Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Leap Therapeutics in a research report ...

H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its ...

Leap Therapeutics (NASDAQ:LPTX – Get Free Report) was downgraded by Baird R W from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports. Several other ...

Leap Therapeutics, Inc.’s LPTX share price has dipped by 71.11%, which has investors questioning if this is right time to buy ...

Leap Therapeutics (LPTX) announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab in combination with ...

H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...